{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:40:23Z","timestamp":1793338823493,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to evaluate the efficacy and safety of telitacicept addition to standard therapy in adults with relapsing lupus nephritis (LN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 2021 to 2024, patients with relapsing LN were identified and divided into two groups based on telitacicept administration. Laboratory indicators, renal remission status, Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores, glucocorticoid dosages, and the incidence of renal flares were evaluated. Multivariate regression was used to assess the baseline predictors of complete renal remission (CRR) and adverse events (AEs) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to the standard therapy group (n=20), the proportion of patients who achieved a CRR and the primary efficacy renal response were significantly increased in the telitacicept group (n=20) at 6, 9, and 12 months, while the reduction rates of 24-hour urinary protein from baseline at 1, 3, and 9 months were significantly higher. The telitacicept group showed notable improvement in treatment responses in the median SLEDAI-2K score and glucocorticoid dose. Multivariate Cox regression analysis revealed that add-on telitacicept was associated with achieving early CRR. At the end of the follow-up period, the cumulative relapse rate in the telitacicept group was significantly lower than that in the standard treatment group, with no increase in the incidence of AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As an add-on therapy, telitacicept is associated with early disease remission in patients with relapsing LN with reduced disease activity, lower glucocorticoid dosage, and fewer relapses. It also showed a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1826829","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:09:53Z","timestamp":1779430193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of telitacicept as an add-on therapy for relapsing lupus nephritis: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Cui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nephrology and Rheumatology, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, The Second Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko","year":"2006","journal-title":"Lupus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100688","article-title":"Novel therapeutics for management of lupus nephritis: what is next","volume":"5","author":"Thakare","year":"2023","journal-title":"Kidney Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000001003","article-title":"Emerging biologic therapies for systemic lupus erythematosus","volume":"36","author":"Kato","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000887","article-title":"Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells","volume":"35","author":"Bhargava","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL-targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflammation Regener"},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/modpathol.2010.184","article-title":"Intrarenal production of B-cell survival factors in human lupus nephritis","volume":"24","author":"Neusser","year":"2011","journal-title":"Mod Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2019.100027","article-title":"Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers","volume":"3","author":"Aguirre-Valencia","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"Van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1613790","article-title":"Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114596","article-title":"Efficacy and safety of telitacicept in patients with class III\u2013V lupus nephritis: a real-world retrospective cohort study","volume":"154","author":"Chen","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf049","article-title":"Real-world data on dual BLyS\/APRIL inhibition with telitacicept for lupus nephritis","volume":"40","author":"Jin","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02501-x","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study","volume":"28","author":"Huang","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad055","article-title":"Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)","volume":"16","author":"Rojas-Rivera","year":"2023","journal-title":"Clin Kidney"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130030","article-title":"Systemic lupus erythematosus disease activity index","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001074","article-title":"Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study","volume":"10","author":"Jin","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1645826","article-title":"Research paper efficacy and safety of telitacicept combined with standard therapy for lupus nephritis: a single-center real-world study","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab067","article-title":"Glucocorticoids in patients with immune-mediated inflammatory diseases: a neglected cardiovascular risk factor","volume":"42","author":"Galiuto","year":"2021","journal-title":"Eur Heart J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3492-6","article-title":"Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus","volume":"36","author":"Tarr","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07348-5","article-title":"Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single-center, retrospective, real-world study","volume":"44","author":"Fang","year":"2025","journal-title":"Clin Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1826829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:09:54Z","timestamp":1779430194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1826829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1826829"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1826829","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1826829"}}